Optimization of PSA screening policies: A comparison of the patient and societal perspectives

Medical Decision Making

Volumn 32, Issue 2, 2012, Pages 337-349

  Zhang, Jingyu ^a   Denton, Brian T ^b   Balasubramanian, Hari ^c   Shah, Nilay D ^d   Inman, Brant A ^e  

^a PHILIPS RESEARCH LABORATORIES   (Netherlands)

^b North Carolina State University   (United States)

^c University of Massachusetts   (United States)

^d MAYO CLINIC   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

partially observable Markov decision process; patient perspective; prostate cancer; PSA; societal perspective

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ARTICLE; ATTITUDE TO HEALTH; BAYES THEOREM; BLOOD; COMPARATIVE STUDY; EARLY DIAGNOSIS; HUMAN; INDIVIDUALITY; MALE; NEEDLE BIOPSY; PATHOLOGY; PATIENT ATTITUDE; PRACTICE GUIDELINE; PROBABILITY; PROSTATE; PROSTATE TUMOR; PSYCHOLOGICAL ASPECT; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; STATISTICS; UNITED STATES;

ATTITUDE TO HEALTH; BAYES THEOREM; BIOPSY, NEEDLE; EARLY DETECTION OF CANCER; EARLY DIAGNOSIS; GUIDELINE ADHERENCE; HUMANS; INDIVIDUALITY; MALE; MARKOV CHAINS; MINNESOTA; PATIENT ACCEPTANCE OF HEALTH CARE; PROBABILITY; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; TUMOR MARKERS, BIOLOGICAL;

EID: 84859304024     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X11416513     Document Type: Review

References (42)

1. Holmstrom B, Johansson M, Bergh A, Stenman UH, Hallmans G, Stattin P. Prostate specific antigen for early detection of prostate cancer: longitudinal study. Br Med J. 2009 ; 339: b3537
2. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002 ; 94 (13). 981-90 (Pubitemid 34814727)
3. WelchHGBlackWC. Overdiagnosis in cancer. J Natl Cancer Inst. 2010;102(9):605-13. Available from: URL: http://dx.doi.org/10.1093/jnci/djq099
4. Haas GP, Delongchamps NB, Jones RF, et al. Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst. 2007 ; 99: 1484-9
5. Woolf SH, Rothemich SF. Screening for prostate cancer: the roles of science, policy, and opinion in determining what is best for patients. Annu Rev Med.. 1999 ; 50: 207-21 (Pubitemid 29117062)
6. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, Prostate Cancer Eearly Detection V.2.; 2007. Online booklet available at www.nccn.org.
7. Etzioni R, Cha R, Cowen ME. Serial prostate specific antigen screening for prostate cancer: a computer model evaluates competing strategies. J Urol.. 1999 ; 162: 741-8 (Pubitemid 29436864)
8. Prostate Specific Antigen Best Practice Statement: 2009 Update. Linthicum, MD: American Urological Association Education and Research ; 2009:
9. Woolf SH. Screening for prostate cancer with prostate-specific antigen: an examination of the evidence. N Engl J Med.. 1995 ; 333 (21). 1401-5
10. SchroderFHHugossonJRoobolMJ. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med.2009;360(13):1320-8. Available from: URL: http://dx.doi.org/10.1056/NEJMoa0810084
11. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med.. 2008 ; 149 (3). 185-91
12. AndrioleGLCrawfordEDGrubbRL. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med.2009;360(13):1310-9. Available from: URL: http://dx.doi.org/10.1056/NEJMoa0810696
13. PinskyPFBlackAKramerBSMillerAProrokPCBergC. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Clin Trials. 2010June. Available from: URL: http://dx.doi.org/10.1177/1740774510374091
14. SchroderFHRoobolMJ. ERSPC and PLCO prostate cancer screening studies: what are the differences?Eur Urol.2010March. Available from: URL: http://dx.doi.org/10.1016/j.eururo.2010.03.033
15. Zhang J, Denton BT, Balasubramanian H, Shah ND, Inman BA Optimization of Prostate Biopsy Referral Decisions. Raleigh, NC: North Carolina State University ; 2009:
16. Lovejoy WS. A survey of algorithmic methods for partially observed Markov decision processes. Ann Oper Res.. 1991 ; 28: 47-66
17. Melton LJ. History of the Rochester Epidemiology Project. Mayo Clin Proc.. 1996 ; 71 (3). 266-74
18. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst.. 2006 ; 98 (8). 529-34 (Pubitemid 43898816)
19. Begg CB, Greenes RA. Assessment of diagnostic tests when disease verification is subject to selection bias. Biometrics. 1983 ; 39 (1). 207-15
20. Bubendorf L, Schöpfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1589 patients. Hum Pathol.. 2000 ; 31 (5). 578-83 (Pubitemid 30323983)
21. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. J Am Med Assoc.. 2005 ; 293 (17). 2095-101 (Pubitemid 40617061)
22. Burkhardt JH, Litwin MS, Rose CM, et al. Comparing the costs of radiation therapy and radical prostatectomy for the initial treatment of early-stage prostate cancer. J Clin Oncol.. 2002 ; 20 (12). 2869-75 (Pubitemid 34651516)
23. National Cancer Institute. Surveillance epidemiology and end results [database]; 2008. Available from: URL: http://seer.cancer.gov/
24. Chhatwal J, Alagoz O, Burnside ES. Optimal breast biopsy decision-making based on mammographic features and demographic factors. Oper Res.. 2010 ; 58 (6). 1577-91
25. KulkarniGSFinelliAFleshnerNEJewettMASLopushinskySRAlibhaiSMH. Optimal management of high-risk T1G3 bladder cancer: a decision analysis. PLoS Med.2007;4(9):e284. Available from: URL: http://dx.doi.org/10.1371/journal.pmed. 0040284
26. Bremner KE, Chong CAKY, Tomlinson G, Alibhai SMH, Krahn MD. A review and meta-analysis of prostate cancer utilities. Med Decis Making. 2007 ; 27: 288-98 (Pubitemid 46801746)
27. Heron M. Deaths: Leading causes for 2004. National Vital Statistics Reports. 2007 ; 56 (5). 1-96
28. Rascati KL. The $64,000 question-what is a quality-adjusted life-year worth?. Clin Ther.. 2006 ; 26 (7). 1042-3 (Pubitemid 44380317)
29. Ekwueme DU, Stroud LA, Chen Y. Cost analysis of screening for, diagnosing, and staging prostate cancer based on a systematic review of published studies. Prev Chronic Dis.. 2007 ; 4 (4). 1-17
30. DraismaGEtzioniRTsodikovA. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst.2009;101(6):374-383. Available from: URL: http://dx.doi.org/10.1093/ jnci/djp001
31. Etzioni R, Gulati R, Falcon S, Penson DF. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. Med Decis Making. 2008 ; 28: 323-31 (Pubitemid 351713299)
32. AusGBergdahlSLoddingPLiljaHHugossonJ. Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer-results from a prospective, population-based randomized controlled trial. Eur Urol.2007;51(3):659-664. Available from: URL: http://dx.doi.org/10.1016/j. eururo.2006.07.012 (Pubitemid 46110933)
33. McNaughton-CollinsMFowlerFJCaubetJF. Psychological effects of a suspicious prostate cancer screening test followed by a benign biopsy result. Am J Med.2004;117(10):719-25. Available from: URL: http://dx.doi.org/10.1016/j. amjmed.2004.06.036 (Pubitemid 39482524)
34. Ross KS, Carter HB, Pearson JD, Guess HA. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. J Am Med Assoc.. 2000 ; 284 (11). 1399-405
35. Alagoz O, Maillart LM, Schaefer AJ, Roberts MS. The optimal timing of living-donor liver transplantation. Manage Sci.. 2004 ; 50 (10). 1420-30
36. Denton BT, Kurt M, Shah ND, Bryant SC, Smith SA. Optimizing the start time of statin therapy for patients with diabetes. Med Decis Making. 2009 ; 29 (3). 351-67
37. Shechter SM, Bryce CL, Alagoz O, et al. A clinically based discrete event simulation of end-stage liver disease and the organ allocation process. Med Decis Making. 2005 ; 25 (2). 199-209 (Pubitemid 40411462)
38. AlagozOHsuHSchaeferAJRobertsMS. Markov decision processes: a tool for sequential decision making under uncertainty. Med Decis Making. 2010;30(4):474-83. Available from: URL: http://dx.doi.org/10.1177/ 0272989X09353194
39. Hu C, Lovejoy WS, Shafer SL. Comparison of some suboptimal control policies in medical drug therapy. Oper Res.. 1993 ; 44: 696-709 (Pubitemid 126669547)
40. Hauskrecht M, Fraser H. Planning treatment of ischemic heart disease with partially observable Markov decision processes. Artif Intell Med.. 2000 ; 18: 221-44 (Pubitemid 30089530)
41. Maillart LM, Ivy JS, Ransom S, Diehl K. Assessing dynamic breast cancer screening policies. Oper Res.. 2008 ; 56 (6). 1411-27
42. US Census Bureau. Annual estimates of the population by five-year age groups and sex for the United States: April 1, 2000 to July 1, 2006 (NC-EST2006-01) [database on the Internet]; 2006. Available from: URL: http://www.census.gov/popest/national/asrh/NC-EST2006-sa.html